trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu']
an researcher noted that enhertu should become the standard of care for her2-low, hr+ metastatic breast cancer after findings presented at #asco22 showed that the drug significantly improved survival. 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.